Impact of Medicaid Prior Authorization Requirement for COX-2 Inhibitor Drugs in Nebraska
نویسندگان
چکیده
منابع مشابه
Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients.
BACKGROUND Prior authorization--mandatory advance approval for the use of expensive medications--is now the primary method by which Medicaid programs control expenditures for drugs. However, whether this policy reduces expenditures for specific drugs without causing the unwanted substitution of other drugs or medical services has been largely unstudied. We evaluated the effects of a prior-autho...
متن کاملMedicaid prior authorization policies and imprisonment among patients with schizophrenia.
OBJECTIVE To examine the impact of Medicaid prior authorization for atypical antipsychotics on the prevalence of schizophrenia among the prison population. Study DESIGN We collected drug-level information on prior authorization restrictions from Medicaid programs in 30 states to determine which states had prior authorization requirements before 2004. We linked the regulatory data to a survey ...
متن کاملA physician-friendly alternative to prior authorization for prescription drugs.
OBJECTIVE To determine if the instant approval (IA) process differs from the traditional prior authorization (PA) process in preferred drug channeling, resultant gaps in therapy, and provider dissatisfaction. STUDY DESIGN An interrupted time series analysis using pharmacy claims and a retrospective cohort study. METHODS The study assessed changes in preferred drug use and subsequent cost re...
متن کاملCOX-2 inhibitor.
he developed severe psoriasis responsive only to repeated courses of the then newly available PUVA (psoralen plus UVA radiation) therapy. Between 1973 and 1993 he received PUVA once a week. During treatment no genital protection was used although he had never received UV therapy directly to the genital area. Two years after the onset of psoriasis he developed peripheral inflammatory arthritis. ...
متن کاملPharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan.
OBJECTIVE To determine from a health plan perspective the cost-effectiveness of cyclooxygenase-2 (COX-2) specific inhibitors, with and without a prior-authorization (PA) process. METHODS A modeling exercise was employed, based on prescription drug claims for a managed care organization with 3.8 million health maintenance organization (HMO) and preferred provider organization (PPO) members. Dr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Health Services Research
سال: 2008
ISSN: 0017-9124,1475-6773
DOI: 10.1111/j.1475-6773.2007.00766.x